Salix Pharmaceuticals Ltd. announced a revision in its accounting Thursday that indicated sales of its drugs weren’t as strong as Wall Street had expected, sending shares down as much as 38% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results